2025
NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.
Giridharan T, Suzuki S, Khan A, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz A, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons T, Yaffe M, Zsiros E, Dey P, McGray A, Segal B. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. The Journal Of Immunology 2025 PMID: 40560129, DOI: 10.1093/jimmun/vkaf121.Peer-Reviewed Original ResearchOvarian cancerLAIR-2Immune cellsOverall survivalTumor cellsAssociated with better OSAssociated with worse overall survivalHigh-grade serous ovarian cancerNon-small cell lung cancerSingle-center retrospective analysisTumor-infiltrating immune cellsT-cell suppressor functionLAIR-1Stromal immune cellsT-cell non-responsivenessEpithelial ovarian cancerT cell suppressionSerous ovarian cancerCell lung cancerImmune cell infiltrationT cell proliferationT cell membraneOptimal debulkingMalignant effusionsAdvanced OCA LAIR-1 targeting antibody drug conjugate for hematologic cancers.
Flies D, Barbu E, Kothari P, Kahan S, Maloveste S, Wilcox R, Kim T, Guha U, Langermann S, Panneer Selvam S, Lovewell R. A LAIR-1 targeting antibody drug conjugate for hematologic cancers. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e15022.Peer-Reviewed Original ResearchAntibody drug conjugatesLAIR-1 expressionLAIR-1Hematological cancersTumor cellsKnock-in (KI) miceControl of tumorsDrug conjugatesT-cell lymphomaHematopoietic cell subsetsImmune cell populationsKilling of leukemic cellsRegulate immune activationAnti-tumor activityExpressed high levelsLeukemic cell deathInternalization in vitroIn vitro cytotoxicity assayLymphoma tumorsTumor cell linesCell subsetsImmune activationLymphoma cellsLymphomaTumor model
2023
LAIR-1 agonism as a therapy for acute myeloid leukemia
Lovewell R, Hong J, Kundu S, Fielder C, Hu Q, Kim K, Ramsey H, Gorska A, Fuller L, Tian L, Kothari P, Paucarmayta A, Mason E, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu E, Morawski A, Maloveste S, Cusumano Z, Patel S, Savona M, Langermann S, Myint H, Flies D, Kim T. LAIR-1 agonism as a therapy for acute myeloid leukemia. Journal Of Clinical Investigation 2023, 133: e169519. PMID: 37966113, PMCID: PMC10650974, DOI: 10.1172/jci169519.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaLeukemic stem cellsMyeloid leukemiaPatient-derived xenograft modelsHealthy hematopoietic stem cellsStem cellsCare therapyLAIR-1LSC survivalAML blastsAgonist antibodyTherapeutic strategiesXenograft modelLeukemic cellsTherapeutic potentialHematopoietic stem cellsEffective eradicationTherapyLeukemiaCell deathAgonismSignaling programsCellsPresence of collagenAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply